PHIO - Latest News
Phio Pharmaceuticals Corp. (PHIO), operates in Healthcare / Biotechnology, trades on NASDAQ.
Market capitalization stands near $10.9M. Beta to the broader market is 0.84.
The article list below shows the most recent PHIO headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.
Recent PHIO Headlines
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
feeds.newsfilecorp.com - Oct 13, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - October 13, 2026) - Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b
defenseworld.net - Oct 11, 2026
Phio Pharmaceuticals (NASDAQ: PHIO) is advancing its lead immuno-oncology candidate, PH-762, as a potential neoadjuvant treatment for cutaneous squamo
Phio Pharmaceuticals to Present at The Global Markets Virtual Forum October 8, 2026
feeds.newsfilecorp.com - Oct 6, 2026
Phio invites individual and institutional investors as well as advisors and analysts, to attend online at www. VirtualInvestorConference.
Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference
newsfilecorp.com - Oct 5, 2026
Highlighting its Proprietary INTASYL siRNA Therapeutic Platform and Development Update for Lead PH-762 Program in Cutaneous Squamous Cell Carcinoma Ki
Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference
newsfilecorp.com - Sep 23, 2026
Company to Highlight Next Stage of PH-762 Clinical Development in Cutaneous Squamous Cell Carcinoma King of Prussia, Pennsylvania--(Newsfile Corp. -
How News Affects PHIO Options Pricing
Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PHIO's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.
Frequently asked PHIO news questions
- What is the latest PHIO news headline?
- The most recent PHIO headline (Oct 13, 2026) is "Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.
- How fresh is the PHIO news on this page?
- News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.
- What PHIO news moves options pricing?
- Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.
- How can I track unusual PHIO options activity related to news?
- Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.